US2007107072A1PendingUtilityA1

Transgenic amphibian models for lymphatic vessel development

50
Assignee: CARMELIET PETERPriority: Nov 7, 2003Filed: Nov 8, 2004Published: May 10, 2007
Est. expiryNov 7, 2023(expired)· nominal 20-yr term from priority
Inventors:Peter Carmeliet
C12N 2830/008A01K 67/0275A01K 2267/0393A61K 49/0008A01K 2217/05A01K 2227/50A01K 2267/0375C12N 15/8509
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides molecular tools for the visualization of the lymphatic vessel system in amphibian. Furthermore, the invention provides assays that allow screening for compounds able to modulate lymphangiogenesis.

Claims

exact text as granted — not AI-modified
1 . A transgenic  Xenopus  comprising a gene that is specifically expressed in the lymphatic vessel system of said  Xenopus.    
     
     
         2 . A transgenic  Xenopus  according to  claim 1  wherein said gene encodes for a reporter gene or a biologically relevant transgene.  
     
     
         3 . A method to produce a transgenic  Xenopus  according to claims  1 - 2  comprising introducing a vector comprising a gene under control of a promoter specifically expressed in the lymphatic vascular system into cells of  Xenopus.    
     
     
         4 . A method according to  claim 3  wherein said promoter is selected from the list comprising Podoplanin promoter, Prox-1 promoter, VEGFR-3 promoter and LYVE-1 promoter.  
     
     
         5 . A method for visualizing the lymphatic vessel system in  Xenopus  comprising generating a transgenic  Xenopus  comprising a reporter gene that is specifically expressed in the lymphatic vessel system.  
     
     
         6 . Use of a transgenic  Xenopus  according to claims  1 - 2  to identify a compound capable of modulating lymphatic vessel development comprising: 
 a) contacting said transgenic  Xenopus  with a test compound,    b) comparing the lymphatic vessel system in said transgenic  Xenopus  contacted with said test compound with the lymphatic vessel system of a transgenic  Xenopus  that was not contacted with said test compound and,    c) determining the effect of said test compound on lymphatic vessel development, such that if lymphatic vessel development in the transgenic  Xenopus  contacted with said test compound is different from the lymphatic vessel development in the transgenic  Xenopus  that was not contacted with said test compound, said compound is a modulator of the lymphatic vessel system.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.